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Abstract
Background—Increasingly, women with stage 2 and 3 breast cancers receive neoadjuvant 
therapy, after which many are eligible for breast-conserving surgery (BCS). The question often 
arises as to whether BCS, if achievable, provides adequate local control. We report the results of 
local recurrence (LR) from the I-SPY 1 Trial in the setting of maximal multidisciplinary treatment 
where approximately 50 % of patients were treated with BCS.
Methods—We analyzed data from the I-SPY 1 Trial. Women with tumors ≥3 cm from nine 
clinical breast centers received neoadjuvant doxorubicin, cyclophosphamide and paclitaxel 
followed by definitive surgical therapy, and radiation at physician discretion. LR following 
mastectomy and BCS were analyzed in relation to clinical characteristics and response to therapy 
as measured by residual cancer burden.
Results—Of the 237 patients enrolled in the I-SPY 1 Trial, 206 were available for analysis. 
Median tumor size was 6.0 cm, and median follow-up was 3.9 years. Fourteen patients (7 %) had 
LR and 45 (22 %) had distant recurrence (DR). Of the 14 patients with LR, nine had synchronous 
DR; one had DR > 2 years later. Only four (2 % of evaluable patients) had LR alone. The rate of 
LR was low after mastectomy and after BCS, even in the setting of significant residual disease.
Conclusions—Overall, these patients at high risk for early recurrence, treated with maximal 
multidisciplinary treatment, had low LR. Recurrence was associated with aggressive biological 
features such as more advanced stage at presentation, where LR occurs most frequently in the 
setting of DR.
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Breast cancer is a heterogeneous disease, and some patients have a higher risk of recurrence 
than others. Patients who present with large palpable tumors are known to have higher risk 
of recurrence relative to those with tumors found by screening.1–3 Increasingly, other 
biological features of the tumor are also known to predict recurrence risk and affect response 
to therapy.4–6 For many high-risk patients, neoadjuvant chemotherapy is used both to 
downstage patients and enable breast-conserving surgery (BCS)7 and evaluate response to 
therapy.
Patients who have a good response to neoadjuvant chemotherapy and have minimal residual 
disease have improved survival compared with those who have considerable residual disease 
present.2,3,8–13 Data regarding the outcome of BCS in downstaged patients are needed to 
inform choices of local therapy after neoadjuvant therapy. Small studies suggest low 
ipsilateral breast tumor recurrence (IBTR) in the neoadjuvant setting.14 Other studies [e.g. 
National Surgical Adjuvant Breast and Bowel Project (NSABP)-18] suggest increased IBTR 
after neoadjuvant chemotherapy, although this did not persist with time and was related to 
younger age.7
The I-SPY 1 Trial is a multicenter neoadjuvant chemotherapy observational study of women 
with histologically confirmed breast cancer. We report the local recurrence (LR) in the 
context of the distant recurrence (DR) rate in this group of patients treated with maximal 
multidisciplinary treatment, and assess the recurrence rates associated with clinical and 
biological characteristics in the context of surgical treatment (BCS vs. mastectomy).
METHODS
Study Design and Patient Selection
The I-SPY 1 Trial was a collaboration of the American College of Radiology Imaging 
Network (ACRIN), Cancer and Leukemia Group B (CALGB), and Specialized Program of 
Research Excellence (SPORE). Details of the trial have been published previously.5,6,15 
Briefly, eligible patients with histologically-confirmed invasive breast cancer ≥3 cm were 
treated with an anthracycline-based chemotherapy regimen plus optional taxane. Axillary 
surgery was conducted post-chemotherapy, although sentinel node alone was allowed for 
patients who presented with clinically node-negative disease. Choice of mastectomy or BCS 
was at the physicians’ discretion. Radiation after breast conservation was standard but post-
mastectomy radiation was determined on an individual basis.
Clinical and Molecular Biomarkers
Hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2)-neu status 
and Ki-67 scoring were determined on pretreatment core biopsies as previously described.6 
The presence of lymphovascular invasion (LVI) was recorded on case-report forms and 
taken from the pathology report.
Evaluation of Response to Therapy Using Pathologic Data
Residual cancer burden (RCB) was determined using the dimensions of the primary tumor 
bed, proportion of primary tumor bed that is invasive cancer, the number of positive nodes, 
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and the size of the largest nodal metastasis, as previously described.16 In addition, the MD 
Anderson Prognostic Index (MDAPI) score, derived to predict local and ipsilateral 
recurrences after BCS following neoadjuvant chemotherapy, was computed based on initial 
node status, pathologic tumor size, morphology of residual disease, and LVI as previously 
described.17,18
Statistical Analysis
The endpoints of interest were LR and DR. Following DR, LR is often not reported; 
however, we queried every site to determine whether an LR had occurred after the time of 
DR up to the point of last follow-up. We used the Chi-square test to assess the association 
between clinical parameters and surgical treatment type for categorical variables, and the 
Mann–Whitney U test for continuous variables. Kaplan–Meier curves and the log-rank test 
were used to assess the association between clinical variables and recurrence over all cases, 
and stratified by surgical treatment type. Time to LR and time to first recurrence (local 
and/or distant) were censored at 5 years in the survival analysis.
RESULTS
A total of 237 patients enrolled in the I-SPY 1 Trial between May 2002 and March 2006. As 
shown in the CONSORT diagram (Fig. 1), 206 patients with complete information were 
available for this analysis. Patient characteristics are shown in Table 1. After a median 
follow-up of 3.9 years, 14 patients (7 %) had LR, and 45 patients (22 %) had DR. Of the 
patients with LR, 10 (22 %) had both an LR and DR (Table 2), four of which were 
synchronous, five of which occurred less than 1 year prior to the diagnosis of metastatic 
disease, and one that preceded the metastatic diagnosis within 2 years (Table 2). LR alone 
occurred in only four patients (2 %). A 2 × 2 table of distant and LR is shown in 
supplemental Table 1 (see electronic supplementary material).
Ninety patients (44 %) had BCS, and 116 patients (56 %) had mastectomy. Not 
unexpectedly, BCS patients had a lower overall clinical (presenting) stage and clinical T 
stage than the mastectomy group. However, these groups did not differ in other biological 
characteristics (Table 1).
As published previously,6 clinical variables associated with recurrence included clinical 
stage, nodal status, RCB and LVI (LR and/or DR) with log rank p < 0.0001, 0.0002, 0.03, 
<0.0001, respectively. Kaplan–Meier curves of time to first recurrence (LR and/or DR) 
within the mastectomy and BCS groups, stratified by dichotomized clinical stage and node 
positivity, are shown in Fig. 2a and b. Patients presenting with clinical stage 3 or 
inflammatory disease have higher overall 5-year recurrence risk (41 and 37 % for the 
mastectomy and BCS groups) when compared with lower-stage patients (5 and 9 % in the 
mastectomy and BCS groups, respectively). Overall 5-year recurrence risks for node-
positive disease at presentation were 36 and 29 %, and for node-negative disease were 11 
and 6 % in the mastectomy and BCS groups, respectively.
We then evaluated whether the factors predicting recurrence risk overall also associate with 
LR risk in an exploratory analysis, and found that higher clinical stage at presentation and 
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LVI were associated with significantly higher risk of LR (log rank p: 0.007 and 0.008). 
Figure 2c and d show the Kaplan–Meier curves for time to LR within the mastectomy and 
BCS groups, stratified by dichotomized clinical stage and LVI, respectively. Patients 
presenting with stage 3 or inflammatory disease have higher 5-year LR risk (11 and 15 %) 
compared with patients presenting with stage 2 (2 and 2 %) for the mastectomy and BCS 
groups, respectively. Patients positive for LVI are also at a higher risk for LR, with 5-year 
rates of 24 and 9 % compared with 4 and 7 % when LVI is not present, for the mastectomy 
and BCS groups, respectively. Interestingly, patients with LVI who underwent BCS did not 
have a higher LR rate. Radiation may play a role; as in the BCS group, 12/13 (92 %) 
patients with LVI received radiation, while, in contrast, in the mastectomy group, 17/23 (74 
%) patients with LVI received post-mastectomy radiation. However, the numbers are too 
small to make any definitive conclusions.
In patients who had radiation, the 5-year LR risk was low within both the mastectomy (6 %) 
and BCS (7 %) groups, and appears to be similar to that observed in patients who did not 
receive radiation (16 % in the mastectomy group and 9 % in the BCS group). However, we 
recognize that radiation treatment was not randomized and was likely influenced by tumor 
clinical and biological characteristics which may bias these findings.
Of the 90 BCS-treated patients, only 56 had complete information to allow MDAPI score 
computation for LR risk prediction. Consistent with the low overall LR risk within the I-
SPY Trial, 73 % of our BCS group were classified as MDAPI low risk; 19 % were classified 
as immediate risk; and only 7 % were classified as high risk. No significant differences in 
LR risk were observed between the MDAPI risk groups (p = 0.583).
Patients were not randomized to surgical procedure following chemotherapy. Therefore, we 
are presenting the following data without any statistical inferences. In the setting of an 
excellent response to therapy (RCB 0 or RCB 1), the 5-year LR risk was 0 % for 
mastectomy and 9 % for breast conservation (Fig. 3b). In the setting of significant residual 
disease (RCB 2 or 3) (Fig. 3c), the LR rate was 12 % for mastectomy and 7 % for breast 
conservation. The majority of the LRs (79 %) were in the RCB 2/3 group (11/14) compared 
with the RCB 0/1 (3/14) group.
DISCUSSION
LR after BCS post-neoadjuvant chemotherapy ranges from 5 to 20 %.2,19–24 After 
mastectomy, the range is from 4 to 28 %.24–26 Fisher et al. found that patients who have 
BCS after being downstaged by neoadjuvant chemotherapy had a higher recurrence than 
those patients undergoing BCS who were eligible for lumpectomy from the beginning, 
although this observation did not hold true with longer follow-up and was related to younger 
age.27 Some would argue that these patients would not have recurred if they had undergone 
mastectomy. The question remains whether mastectomy would have helped counteract 
aggressive biology, or whether the patients with aggressive biology would have recurred 
with either type of surgery.
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Biologic characteristics such as advanced stage at presentation, nodal status, receptor status, 
LVI, multifocality, and response to therapy have been shown to affect recurrence rates after 
neoadjuvant chemotherapy.3,5,6,8–13,25,28,29 Paradoxically, higher-risk molecular profiles 
(HER2+ or TN, for example) have been shown to be associated with higher likelihood of 
achieving a complete pathologic response, which in turn predicts better disease-free 
survival, as reported by the I-SPY Trial investigators and others.5,6,30,31 Failure to achieve a 
complete or near complete pathologic response in these same patients is associated with 
increased risk of recurrence-free survival.5,6 These same factors appear to predict recurrence 
whether patients undergo BCS or mastectomy.
For patients who meet the I-SPY Trial eligibility criteria, the biggest risk is DR. LR alone 
was rare (2 %), and DR was three times more common than LR. LR strongly predicted DR. 
A potential flaw in these data is that once DR is reported, the procedure for assessing LR is 
different and less likely to be complete; however, we specifically queried all sites to 
determine whether patients who had DR had experienced a delayed LR.
Likely, the systemic therapy controlled not only distant but also local disease, and in this 
setting, when response to therapy was excellent, BCS and mastectomy both resulted in low 
LR. The overwhelming majority of patients received radiation therapy, and this likely 
contributed to local control as well. Maximal multidisciplinary treatment may also have 
resulted in more optimal selection of patients for breast conservation. Patients in this study 
underwent serial imaging and multiple visits, and had coordinated surgical and medical 
oncology care, which may also have contributed to better local outcomes.
The MDAPI is reported to predict a 5-year LR in BCS-treated patients following 
neoadjuvant chemotherapy.17,18 The MDAPI did not appear predictive of LR risk in the I-
SPY Trial BCS-treated patients. It is not apparent why our results are different as systemic 
treatments were similar, as was high use of radiation in both the MD Anderson cohorts and 
the I-SPY multisite trial. This lack of association may be attributed to an important 
limitation in our exploratory analysis evaluating factors predicting LR risk. Our sample size 
was small, and given that the LR risk within our study was low, we may not be inadequately 
powered to detect differences between risk groups.
We have reported previously that most patients will have significant shrinkage of tumor 
after neoadjuvant therapy and many will be able to achieve breast conservation. Patients 
with more circumscribed masses, based on magnetic resonance imaging phenotypes, are 
more likely to achieve shrinkage that will enable BCS.32 In this study, we demonstrate that 
for those patients who are able to achieve breast conservation, the LR rates are low, even 
when tumors are large at presentation.
A potential limitation of the study is the length of follow-up as HR+ tumors may take longer 
to recur.4 However, based on data from the Early Breast Cancer Trialists’ Collaborative 
Group Overview data, 75–85 % of all LRs occur in the first 5 years in node-positive 
patients.33 The key limitation of our study is that the choices of surgery and radiation 
therapy were not randomized. Certainly, patients who cannot have breast conservation due 
to large tumor-to-breast ratio or significant residual disease will be much more likely to have 
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mastectomy. This likely explains the particularly high LR rate in the mastectomy patients 
with residual disease and LVI. Additionally, most patients presenting with inflammatory 
breast cancer underwent mastectomy. However, we note that with the exception of clinical 
stage and T stage at presentation, the BCS and mastectomy groups were not different with 
respect to other biologic factors.
Despite these limitations, there are a few insights that merit testing in future studies. As the 
majority of LRs occur in the RCB 2/3 arm, perhaps local management should be driven by 
residual disease and LVI. The numbers of patients in the I-SPY 1 cohort are not large 
enough to make definitive conclusions, and we plan to re-evaluate our findings in an 
expanded cohort once the I-SPY 1 extension 3-year EFS data become available.
For the majority of patients in the I-SPY1 Trial, recurrence came in the form of distant 
metastasis. Both mastectomy and breast conservation were associated with relatively low 
and acceptable LR rates. High-risk factors (advanced stage at presentation, poor response to 
therapy, and LVI) increased the chance of LR in the setting of both mastectomy and BCS. 
Going forward, there may be an opportunity to reduce the extent of treatment after 
neoadjuvant therapy for groups of patients with less risky biological features, especially 
those who have a pathologic complete response and choose mastectomy. Radiation therapy 
may not add much value as the LR risk is already low. Larger randomized trials of 
neoadjuvant therapy from NSABP have resulted in the identification of patient groups who 
would likely not have a survival benefit from post-mastectomy radiation.34 Given that 
radiation after mastectomy, especially in the setting of reconstruction, is associated with 
higher complications and additional procedures,35–38 this could be an important contribution 
to improving treatment options and outcomes. We recognize that in this study, radiation was 
given at the physicians’ discretion, with 28 of 36 RCB 0/1 patients who received 
mastectomy (Fig. 3a) also receiving radiation. In comparison, 64/73 patients in the RCB 2/3 
mastectomy group received radiation. As neoadjuvant trials and treatment become more 
common, a randomized controlled trial of radiation versus no radiation after good response 
to neoadjuvant therapy and/or low-risk biologic features, in the setting of mastectomy, 
would be of clinical importance. The information would be of great value to patients and 
their treating physicians.
After neoadjuvant chemotherapy, there will still be patients with large residual tumor-to-
breast ratio or diffuse disease, and patients who prefer mastectomy. These are the indications 
for mastectomy after neoadjuvant chemotherapy, not findings of aggressive biology, as 
aggressive biology dictates recurrence in patients after either type of surgery. We can 
counsel patients that BCS and mastectomy are both oncologically safe. Patients, especially 
those who are likely to undergo radiation, may be able to decrease local complications by 
undergoing BCS with acceptable rates of local control.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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CONSORT diagram of patients available for analysis. HR hormone receptor, HER2 human 
epidermal growth factor receptor 2
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Kaplan–Meier analysis of time to recurrence within mastectomy and BCSS subsets. a,b 
Kaplan–Meier curves of time to first recurrence (LR and/or DR) within mastectomy (dotted 
line) and BCSS (solid line) subsets were stratified by a dichotomized clinical stage at 
presentation (gold stage 2 or below; blue stage 3 or inflammatory); b nodal status at 
presentation (gold node negative; blue node positive). c,d Kaplan–Meier curves of time to 
LR within the mastectomy (dotted line) and BCSS (solid line) subsets were stratified by c 
dichotomized clinical stage at presentation (gold stage 2 or below; blue stage 3 or 
inflammatory); d LVI at surgery (gold negative; blue positive). p-Values refer to the 
difference in either first time to recurrence (a,b) or LR (c,d) dichotomized by clinical stage, 
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node status, and LVI within each surgical type. LR local recurrence, DR distant recurrence, 
LVI lymphovascular invasion, BCS breast-conserving surgery
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LR in the context of response to therapy within mastectomy and BCS subsets. a Recurrence 
in patients with good or poor response to therapy by surgery type. b Kaplan–Meier curves of 
time to LR within mastectomy (dotted line) and lumpectomy (solid line) subsets in patients 
with good response to therapy (RCB 0/1). c Kaplan–Meier curves of time to LR within 
mastectomy (dotted line) and lumpectomy (solid line) subsets in patients with poor response 
to therapy (RCB 2/3). LR local recurrence, DR distance recurrence, BCS breast-conserving 
surgery, RCB residual cancer burden
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TABLE 1
Patient characteristics and comparison between the BCS and mastectomy groups
Patient characteristics All cases BCS group Mastectomy group p-Value
Total patients [n (%)] 206 90 (44) 116 (56)
Age [years; median (range)] 49.1 (26–68) 50.0 (27–68) 47.6 (26–67) 0.04
Race [% (n)]
  Caucasian 75 (155) 73 (66) 77% (89) 0.92
  African American 18 (37) 20 (18) 21% (24)
  Asian 4 (9) 4 (4) 4% (5)
  Other 2 (5) 1 (1) 1% (3)
Clinical tumor size [cm; median (range)] 6.0 (0–25) 5.0 (1–14) 7.0 (0–25) <0.0001
Clinical T stage (n = 204) [% (n)]
  1a 2 (5) 2 (2) 3 (3) 0.0001
  2 35 (73) 51 (46) 23 (27)
  3 50 (104) 41 (37) 58 (67)
  4 11 (22) 4 (4) 16 (18)
Clinically node positive [% (n)] 64 (131) 61 (55) 66 (76) 0.47
Clinical stage (n = 205) [% (n)]
  Ia 1 (3) 1 (1) 2 (2) 0.0006
  II 47 (96) 60 (54) 36 (42)
  III 44 (91) 37 (33) 49 (57)
  Inflammatory 8 (16) 1 (1) 13 (15)
Histologic grade [% (n)]
  I 7 (15) 10 (9) 5 (6) 0.36
  II 47 (96) 47 (42) 44 (51)
  III 46 (95) 41 (37) 50 (58)
  Indeterminate 1 (3) 2 (2) 1 (1)
Receptor status [% (n)]
  HR (+) 60 (123) 54 (49) 64 (74) 0.20
  HER2 (+) 32 (66) 31 (28) 33 (38) 0.88
  HR (+) HER2 (−) 44 (90) 40 (36) 47 (54) 0.53
  HR (−) HER2 (−) 24 (50) 29 (26) 21 (24)
  HR (−) HER2 (+) 16 (33) 17 (15) 16 (18)
  HR (+) HER2 (+) 16 (33) 14 (13) 17 (20)
Ki-67 [% (n)]
  Low (<10 %) 24 (49) 24 (19) 29 (26) 0.35
  Medium (10–25 %) 30 (61) 31 (24) 36 (32)
  High (>25 %) 34 (70) 45 (35) 34 (31)
  Indeterminate 13 (26)
Residual cancer burden [% (n)] n = 192 n = 109 n = 83
  0 26 (54) 34 (28) 24 (26) 0.45
  1 9 (18) 10 (8) 9 (10)
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Patient characteristics All cases BCS group Mastectomy group p-Value
  2 41 (84) 41 (34) 46 (50)
  3 7 (14) 16 (13) 21 (23)
Lymphovascular invasion [% (n)] 17 (36) 15 (13) 20 (23) 0.46
Total receiving radiation [% (n)] 83 (170) 87 (78) 79 (92) 0.20
Total receiving taxane [% (n)] 5 (11) 6 (5) 5 (6) 1
BCS breast-conserving surgery, HR hormone receptor, HER2 human epidermal growth factor receptor 2
a
As of data lock in February 2012
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TABLE 2
Local versus DR by time of recurrence (total n = 206)
Time from original cancer to first recurrence No LR Time between LR and DR
DR only Synchronous Within 1 year Within 2 years Within 5 years No DR
0–2 years 19 2 4 1 3
2–5 years 15 2 1
>5 years 1 1
Total recurrences 35 10 4
No recurrence 157
DR distant recurrence, LR local recurrence
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